ONCY
Oncolytics Biotech
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 2
consensus rating "Strong Buy"
Bearish Engulfing
EPS Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About ONCY
Oncolytics Biotech Inc.
A Canadian company that develops oncolytic viruses for the treatment of cancers
Biological Technology
04/02/1998
06/01/2018
NASDAQ Stock Exchange
28
12-31
Common stock
804, 322 11th Avenue SW, Calgary, Alberta, Canada T2R 0C5
--
Oncolytics Biotech Inc., was incorporated on April 2, 1998 under the laws of Alberta as an Alberta limited liability company. The company is a clinical-stage biopharmaceutical company developing pelareorep, a safe and well-tolerated intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the immune system's ability to fight cancer, making tumors more vulnerable to extensive tumor treatment.
Company Financials
EPS
ONCY has released its 2024 Q4 earnings. EPS was reported at -0.10, versus the expected -0.09, missing expectations. The chart below visualizes how ONCY has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available